Recombinant protein purification |
(VPGXG)36 X=K1V7F1
|
Cecropin AD antimicrobial peptide with enterokinase cleavage site |
[31] |
(VPGXG)90 X=V5A2G3
|
Halocidin18 antimicrobial peptide with hydroxylamine cleavage site |
[34] |
(VPGXG)110 X=V5A2G3
|
Moricin CM4 and human β-defensin 4 antimicrobial peptides with intein cleavage sites |
[37] |
(VPGVG)240
|
SrtA transpeptidase for site-specific cleavage and triglycine addition |
[38] |
(VPGXG)90 X=A2G3V5
|
TNFα and TRAIL apoptosis-inducing cytokines with SrtA cleavage sites |
Therapeutic protein ELP fusions |
(VPGXG)90 X=V5G3A2
|
IL-1ra anti-inflammatory cytokine |
[39] |
(VPGVG)27
|
IL-4 and IL-10 anti-inflammatory cytokines |
[19, 40] |
(VPGVG)n n=5–240 |
IL-10 anti-inflammatory cytokine and EPO hematopoietic cytokine |
[17] |
(VPGXG)100 X=V, G, or A |
HIV neutralizing antibody |
[41] |
(VPGXG)100 X=V5G3A2
|
TNF-VHH inhibitor for prevention of septic shock |
[18] |
Targeted peptide ELP fusions |
[AP1-(VGVPG)12]6
|
AP1 peptide for tumor homing to IL-4 receptor |
[42] |
(VPGXG)120 X=V1G7A8
|
TAT, MTS, and penetratin CPPs for enhanced cellular uptake and intracellular delivery of p21 peptide drug |
[43] |
Therapeutic small molecule drug ELP conjugates |
(VPGXG)150 X=V5A2G3 and (VPGXG)160 X=V1A8G7
|
Lysine residue for conjugation of chemotherapeutic doxorubicin with acid-cleavable hydrazone linker |
[44] |
(VPGXG)180 X=V5A2G3
|
Cysteine residue for conjugation of chemotherapeutic doxorubicin with acid-cleavable hydrazone linker |
[45] |
(VPGXG)150 X=V5A2G3 and (VPGXG)160 X=V1A8G7
|
Cysteine residue for conjugation of chemotherapeutic doxorubicin with enzyme-cleavable peptide linker and TAT CPP for enhanced cellular uptake |
[46] |
Block copolymer ELP assemblies |
(VPGXG)96 [X=V1A8G7]-(VPGVG)60
|
RGD and NGR peptide at hydrophilic terminus for multivalent display of ligands for receptors on tumor vasculature |
[47] |
(VPGXG)64 [X=V1A8G7]-(VPGVG)90
|
NGR peptide at hydrophilic terminus for multivalent display of ligand for CD13 receptors on tumor vasculature |
[48] |
(VPGSG)48-(VPGIG)48
|
Knob protein at hydrophilic terminus for multivalent display of CAR ligand |
[49] |
FKBP protein at hydrophilic terminus for rapamycin drug binding |
[50, 51] |
Conjugation-driven ELP assemblies |
(VPGXG)160 X=V1A8G7
|
(GGC)8 peptide for conjugation of chemotherapeutic doxorubicin |
[52] |
C(GGC)7 peptide for conjugation of chemotherapeutic paclitaxel |
[53] |
ELP polyplexes |
(VPGXG)60 X=V5A2G3
|
K8 cationic peptide for ionic complexation with GFP-encoding plasmid DNA |
[54] |
Coacervate ELP nanoparticles |
(VPAVG)220
|
Physical encapsulation of BMP-2 and BMP-14 cytokines for promotion of bone growth |
[55] |
[VG-(VPGVG)4-VPG]8-[VG-(VPGVG)2-VPGCG-VPGVG-VPG]2
|
KGF protein for promotion of wound healing |
[56] |
Cross-linked ELP particles |
[(VPGVG)4-(VPGKG)]8-(VPGVG)40
|
Lysine residues for glutaraldehyde cross-linking of solid microparticles with physical loading of model drugs BSA and prednisone acetate |
[57] |
[(VPGVG)14-(VPGKG)]8-(VPGVG)40
|
Lysine residues for glutaraldehyde cross-linking of core-shell microparticles with physical loading of model drugs rhodamine B, FITC, and rhodamine-BSA |
[58] |
EP20–244 (composed of exons from human elastin: 20-(21-23-24)4) |
Lysine and glutamine residues for transglutaminase cross-linking of hollow spheres with physical loading of plasmid DNA polyplexes |
[59] |